Lanreotide 120 Mg Injection

Acromegaly is a chronic endocrine and metabolic disorder caused by excessive secretion of growth hormone (GH) from the pituitary gland, mostly due to a GH‑secreting pituitary adenoma. Chronic excess GH leads to overgrowth of systemic soft tissues and bones, causing facial changes, enlarged hands and feet, and visceral hypertrophy. It also increases the risk of hypertension, diabetes, cardiovascular diseases, and other complications, severely impairing quality of life and survival.
The core clinical goals are to control GH and insulin‑like growth factor‑1 (IGF‑1) levels, relieve symptoms, reduce pituitary adenoma volume, and lower complication rates. As a long‑acting SSA, Lanreotide 120 mg Injection mimics the physiological effects of somatostatin, potently inhibits pituitary GH secretion, and exerts antiproliferative effects on pituitary adenoma cells. It is a cornerstone treatment for acromegaly, especially for patients with unsatisfactory surgical outcomes, inoperable disease, or intolerance to surgery or radiotherapy.

Lanreotide 120 mg Injection has a favorable safety profile in acromegaly. Most adverse reactions are mild‑to‑moderate, appear early in treatment, and diminish with continued therapy.
The most common adverse reactions are injection‑site reactions (pain, redness, swelling, induration), but the incidence is significantly lower than with similar drugs, attributed to the nanogel formulation and prefilled syringe design. Most reactions resolve spontaneously within 1–2 weeks without discontinuation.
Other common adverse reactions include gastrointestinal effects (nausea, bloating, diarrhea) and endocrine disturbances (blood glucose fluctuations, mild hypothyroidism). Glucose fluctuations are usually mild and more frequent in patients with diabetes. Blood glucose monitoring is recommended at treatment initiation and during dose adjustments, with antidiabetic medication titrated accordingly. For diabetic patients on insulin, the initial insulin dose should be reduced by 25% and then gradually adjusted.

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms originating from neuroendocrine cells, which can occur throughout the body. Gastroenteropancreatic neuroendocrine tumors (GEP‑NETs) account for approximately 70%. These tumors have complex, non‑specific clinical manifestations and are difficult to diagnose, with a mean time to diagnosis of up to 5 years. About 40%–50% of patients present with distant metastasis at initial diagnosis. The 5‑year survival rate is approximately 54%, and only 7.8% for high‑grade tumors, indicating a poor prognosis.
Treatment of NETs requires individualized strategies based on tumor location, stage, grade, and the patient's general condition. Core goals are to control tumor proliferation, relieve symptoms caused by excessive hormone secretion, and prolong progression‑free survival (PFS) and overall survival (OS).

It demonstrates outstanding efficacy in prolonging PFS and relieving symptoms in neuroendocrine tumors, with advantages over some similar agents.
In a randomized controlled trial (RCT), patients with well‑ or moderately differentiated GEP‑NETs treated with 120 mg every 4 weeks had a median PFS of 30.1 months, compared with 28.0 months for octreotide microspheres (HR = 0.9, 95%CI: 0.71–1.12), effectively delaying tumor progression. Another RCT showed that in patients with well‑ or moderately differentiated G1/G2 GEP‑NETs, the 120 mg dose achieved a median PFS of 32.8 months, significantly higher than 18 months in the placebo group. The pancreatic NET (pNET) subgroup had a median PFS of 29.7 months.

As adjuvant therapy after surgical resection, 120 mg once every 4 weeks for 1 year reduced the recurrence risk of GEP‑NETs by 35%, with a 5‑year OS of 87.5%, significantly higher than 65.6% in the octreotide group.
Furthermore, the convenience of this injection supports long‑term therapy for neuroendocrine tumor patients. As the only SSA approved worldwide for deep subcutaneous self‑injection, 100% of patients prefer self‑or caregiver administration, and 97.8% of nurses recommend this product. Its needle‑ready, rapid injection design reduces clinical burden and improves adherence, ensuring continuous long‑term treatment.
Pharmacoeconomic analysis shows that, compared with long‑acting octreotide, treatment of neuroendocrine tumors with this agent results in substantial annual savings, driven by its favorable pricing, shorter administration time, and lower risk of needle clogging.